37 devices · GMDN 56895
Carcinoembryonic antigen (CEA) in vitro diagnostic (IVD) antibody tests detect traces of CEA proteins in patient samples, such as blood or tissue. Clinically, these tests help monitor cancer progression—particularly colorectal, lung, or breast cancer—and assess treatment response by measuring CEA levels.
These devices are typically classified as in vitro diagnostics and regulated under medical device laws, with requirements varying by jurisdiction. They’re often supplied as kits or reagents for laboratory use, designed for qualitative or quantitative analysis depending on the specific assay format.
This category summary is AI-generated from the GMDN nomenclature and has not been verified by a human reviewer.